Malignant Melanoma | Current Treatment: Physician Insights | US | 2017
The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune checkpoint inhibitors (ICIs) and BRAF/MEK-targeted therapies have changed the treatment landscape dramatically. Combination therapies are playing an increasingly greater role in the unresectable recurrent or metastatic setting, including regimens such as Novartis’s Tafinlar plus Mekinist (2014), Roche/Genentech’s Zelboraf plus Cotellic (2015), and Bristol-Myers Squibb’s Opdivo plus Yervoy (2015). Consequently, optimizing sequencing decisions is a key focus for prescribing oncologists, irrespective of patients’ BRAF mutation status.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis, SSc) is a rare, progressive autoimmune disease marked by skin fibrosis, systemic inflammation, and vasculopathy, leading to Raynaud’s phenomenon and painful…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
